Literature DB >> 16322345

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.

Francesco Panzuto1, Silvia Nasoni, Massimo Falconi, Vito Domenico Corleto, Gabriele Capurso, Sara Cassetta, Michela Di Fonzo, Valentina Tornatore, Massimo Milione, Stefano Angeletti, Maria Sofia Cattaruzza, Vincenzo Ziparo, Cesare Bordi, Paolo Pederzoli, Gianfranco Delle Fave.   

Abstract

Since gastro-entero-pancreatic endocrine tumors are rare and heterogeneous diseases, their prognosis and long-term survival are not well known. This study aimed at identifying prognostic factors and assessing long-term survival in gastro-entero-pancreatic endocrine tumors. A total of 156 patients enrolled. Prognostic factors were determined by univariate/multivariate analysis; survival rates were assessed by the Kaplan-Meier method. The tumors were non-functioning in 59.6% of patients, and originated from the pancreas in 42.9%. At diagnosis, 64.3% of patients had metastases. The tumors were well differentiated in 89.6% of patients. Ki67 was >2% in 39.6% of patients. Primary tumor size was >3 cm in 49.6% of cases studied. For the univariate analysis, the negative prognostic factors were: pancreatic origin (rate ratio 4.64, P = 0.0002), poorly differentiated tumor (rate ratio 7.70, P = 0.0001), primary tumor size >3 cm (rate ratio 4.26, P = 0.0009), presence of distant metastases (liver: rate ratio 5.88, P = 0.01; distant extra-hepatic: rate ratio 13.41, P = 0.0008). The pancreatic site, the poor degree of differentiation and the distant metastases were confirmed as negative prognostic factors at multivariate analysis. Overall 5-year survival rate was 77.5%. Survival rates differed according to: primary tumor site (62% for pancreatic vs 89.9% for gastrointestinal tract, P = 0.0001) and size (65.7% for >3 cm vs 88.8% for < or = 3 cm, P = 0.0003), degree of differentiation (22% for poor vs 86.8% for good, P < 0.0001), Ki67 (53.5% for > 2% vs 90.1% for < or = 2%, P = 0.003), metastases (96.1, 77, 73.3 and 50.1% for absent, local, liver and distant extra-hepatic metastases respectively), age at diagnosis (85.3% for < or = 50 years vs 70.3% for > 50 years, P = 0.03). Although 64.3% of gastro-entero-pancreatic endocrine tumors present metastases at diagnosis, the 5-year survival rate is 77.5%. Pancreatic site, a poor degree of tumor cell differentiation and distant extra-hepatic metastases are the major negative prognostic factors.

Entities:  

Mesh:

Year:  2005        PMID: 16322345     DOI: 10.1677/erc.1.01017

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  128 in total

Review 1.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

Review 2.  Contemporary management of nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Rebecca M Minter; Diane M Simeone
Journal:  J Gastrointest Surg       Date:  2011-10-19       Impact factor: 3.452

3.  Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study.

Authors:  Lingaku Lee; Hisato Igarashi; Nao Fujimori; Masayuki Hijioka; Ken Kawabe; Yoshinao Oda; Robert T Jensen; Tetsuhide Ito
Journal:  Jpn J Clin Oncol       Date:  2015-09-15       Impact factor: 3.019

4.  TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; A Couvelard; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2007-08-03       Impact factor: 4.064

5.  Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al.

Authors:  Davide Campana; Gianfranco Delle Fave; Massimo Falconi; Paola Tommassetti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01       Impact factor: 9.236

6.  IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence.

Authors:  Sara Massironi; Alessandro Del Gobbo; Federica Cavalcoli; Stefano Fiori; Dario Conte; Alessio Pellegrinelli; Massimo Milione; Stefano Ferrero
Journal:  Endocrine       Date:  2017-02-17       Impact factor: 3.633

7.  Grading of EUS-FNA cytologic specimens from patients with pancreatic neuroendocrine neoplasms: it is time move to tissue core biopsy?

Authors:  Rakesh Vinayek; Gabriele Capurso; Alberto Larghi
Journal:  Gland Surg       Date:  2014-11

Review 8.  Laparoscopic resection of pancreatic neuroendocrine tumors.

Authors:  Abbas Al-Kurd; Katya Chapchay; Simona Grozinsky-Glasberg; Haggi Mazeh
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

9.  Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan.

Authors:  Tetsuhide Ito; Hironobu Sasano; Masao Tanaka; R Yoshiyuki Osamura; Iwao Sasaki; Wataru Kimura; Koji Takano; Takao Obara; Miyuki Ishibashi; Kazuwa Nakao; Ryuichiro Doi; Akira Shimatsu; Toshirou Nishida; Izumi Komoto; Yukio Hirata; Kazuhiko Nakamura; Hisato Igarashi; Robert T Jensen; Bertram Wiedenmann; Masayuki Imamura
Journal:  J Gastroenterol       Date:  2010-02       Impact factor: 7.527

10.  Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.

Authors:  Davide Campana; Gabriele Capurso; Stefano Partelli; Francesca Nori; Francesco Panzuto; Domenico Tamburrino; Giulia Cacciari; Gianfranco Delle Fave; Massimo Falconi; Paola Tomassetti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-26       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.